Invesco
KROS icon

Invesco’s Keros Therapeutics KROS Stock Holding History

Invesco’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$766K Sell
71,563
-16,209
-18% -$181K ﹤0.01% 3052
2026
Q1 		$969K Buy
87,772
+344
+0.4% +$5.31K ﹤0.01% 2877
2025
Q4 		$1.78M Buy
87,428
+12,449
+17% +$218K ﹤0.01% 2650
2025
Q3 		$1.19M Buy
74,979
+31,584
+73% +$467K ﹤0.01% 2850
2025
Q2 		$579K Buy
43,395
+10,129
+30% +$137K ﹤0.01% 3099
2025
Q1 		$339K Buy
33,266
+20,650
+164% +$240K ﹤0.01% 3311
2024
Q4 		$200K Buy
12,616
+453
+4% +$23.5K ﹤0.01% 3517
2024
Q3 		$706K Buy
12,163
+298
+3% +$14.7K ﹤0.01% 3075
2024
Q2 		$542K Sell
11,865
-76,818
-87% -$4.13M ﹤0.01% 3245
2024
Q1 		$5.87M Buy
88,683
+78,703
+789% +$4.67M ﹤0.01% 2122
2023
Q4 		$397K Sell
9,980
-6,571
-40% -$206K ﹤0.01% 3330
2023
Q3 		$528K Buy
16,551
+5,409
+49% +$202K ﹤0.01% 3174
2023
Q2 		$448K Buy
11,142
+700
+7% +$30.7K ﹤0.01% 3292
2023
Q1 		$446K Buy
10,442
+2,615
+33% +$132K ﹤0.01% 3323
2022
Q4 		$376K Sell
7,827
-229
-3% -$10.7K ﹤0.01% 3412
2022
Q3 		$303K Buy
+8,056
New +$279K ﹤0.01% 3509
2022
Q2 		– Sell
-6,980
Closed -$379K – 4092
2022
Q1 		$379K Buy
6,980
+43
+0.6% +$2.21K ﹤0.01% 3534
2021
Q4 		$406K Sell
6,937
-690
-9% -$34.4K ﹤0.01% 3476
2021
Q3 		$301K Sell
7,627
-67,877
-90% -$2.42M ﹤0.01% 3654
2021
Q2 		$3.21M Sell
75,504
-115,919
-61% -$6.28M ﹤0.01% 2641
2021
Q1 		$11.8M Buy
191,423
+1,704
+0.9% +$108K ﹤0.01% 1863
2020
Q4 		$13.4M Buy
189,719
+1,637
+0.9% +$103K ﹤0.01% 1658
2020
Q3 		$7.25M Sell
188,082
-113,743
-38% -$4.51M ﹤0.01% 1816
2020
Q2 		$11.3M Buy
+301,825
New +$9.3M ﹤0.01% 1571

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Invesco's KROS Position: Q2 2026 in Review

Invesco reduced its Keros Therapeutics (KROS) stake by 18% in Q2 2026, selling an estimated $181K and leaving 71,563 shares worth $766K. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

Invesco first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $13.4M in Q4 2020. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Invesco held 71,563 shares of Keros Therapeutics worth $766K as of Q2 2026.
  • Invesco sold 16,209 Keros Therapeutics shares in Q2 2026, an estimated $181K.
  • Keros Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3052 holding.
  • Invesco first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Invesco's Keros Therapeutics position peaked at $13.4M in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.